Novel adjuvant therapy for triple negative breast cancer

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R41CA183399-01A1
Agency Tracking Number: R41CA183399
Amount: $225,000.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: 102
Solicitation Number: PA14-072
Timeline
Solicitation Year: 2015
Award Year: 2015
Award Start Date (Proposal Award Date): 2015-04-01
Award End Date (Contract End Date): 2017-03-31
Small Business Information
3393 RAES CREEK ROAD, Marietta, GA, 30008-5702
DUNS: 832442771
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 RUBEN GONZALEZPEREZ
 (404) 752-1581
 rgonzalez@msn.edu
Business Contact
 JAMES LILLARD
Phone: (678) 697-5220
Email: james.lillard@jyanttech.com
Research Institution
 MOREHOUSE SCHOOL OF MEDICINE
 720 WESTVIEW DR SW
ATLANTA, GA, 30310-1495
 Nonprofit college or university
Abstract
DESCRIPTION provided by applicant Triple negative breast cancer TNBC is very difficult to treat and has no specific targeted therapies Chemotherapies used to treat this disease have many undesirable side effects and patients eventually relapse as a result of chemoresistance Obesity is pandemic in the US and many TNBC suffer from this as well Obesity is accompanied by high levels of leptin and is linked to the highest mortality rates in TNBC patients In contrast to normal mammary cells TNBC cells overexpress the leptin receptor and significantly proliferate under leptin interactions Our exciting findings suggest leptin is involved in TNBC acquired drug resistance through the induction of breast cancer stem cells BCSC Anti angiogenic drugs show limited success for TNBC but these shortcomings could be due in part to angiogenic signal redundancy i e leptin JYANT Technologies Inc has designed a proprietary potent and highly specific inhibitor of leptin signaling leptin peptide receptor antagonist LPrA The peptide conjugated to polyethylene glycol kDa PEG wLPrA has a hour half life after intravenous administration and significantly reduces TNBC growth Preliminary data also show that PEG wLPrA does not induce changes in food intake body weight or general health status We propose the use of PEG wLPrA as an adjuvant therapy for TNBC that will improve the efficacy and reduce dosage and toxicities associated with current TNBC therapy e g doxorubicin cyclophosphamide paclitaxel PEG wLPrA will target leptinandapos s proliferative pro angiogenic and BCSC related actions in TNBC This study will evaluate this novel adjuvant therapy in clinically relevant obesity TNBC models Specifically toxicity an adjuvant therapy studies along with doxorubicin cyclophosphamide and or paclitaxel treatments will be carried out in lean and obese mice hosting human and mouse TNBC xenografts and syngeneic grafts The experimental data generated from this STTR Phase I proposal will allow for the rapid translation of an innovative and targeted adjuvant therapy for TNBC This novel strategy will generate an effective therapy for reducing chemoresistance relapse and metastasis of TNBC via depletion BCSC which are maintained by leptin signaling Our proposed studies are of paramount importance for TNBC sufferers especially those that are overweight or obese which shows the highest levels of leptin and TNBC incidence PUBLIC HEALTH RELEVANCE Biunivocal binding affinity activation and oncogenic effects of leptin leptin receptor complex in breast cancer cells makes it a novel molecular target for the treatment of triple negative breast cancer TNBC particularly in the context of obesity The proposed project will test a novel adjuvant therapeutic PEG wLPrA which will significantly impact current TNBC therapy by reducing dosage side effects and improve efficacy

* Information listed above is at the time of submission. *

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government